An Ohio-based biopharmaceutical startup that’s developing new interventions for acute and chronic lung diseases – including for very preterm infants – has closed a $15.5 million oversubscribed Series C financing round.
An Ohio-based biopharmaceutical startup that’s developing new interventions for acute and chronic lung diseases – including for very preterm infants – has closed a $15.5 million oversubscribed Series C financing round.